Event

Cancer immunotherapy and immuno-oncology are rapidly expanding fields. Since immune checkpoint inhibitors targeting CTLA4 and PD1/PDL1 have been FDA approved for a number of cancers including fist line therapy of metastatic NSCLC pulmonary providers are involved in many aspects of cancer immunotherapy. This included assessment of PD-L1 status and management of an increasing number of pulmonary complications of these agents. Understanding of immunotherapy and the appropriate recognition, diagnosis and managementof these potentially life threatening complications are crucial to patient outcomes. This session will provide attendees with the skills to do this in their daily practice.